DNA

Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US Orphan Drug Designation previously…

2 months ago

Konica Minolta Healthcare Receives Innovative Technology Designation from Vizient for Dynamic Digital Radiography

Dynamic Digital Radiography - Shoulder Series DDR is a novel, low-dose X-ray imaging technique available on Konica Minolta Healthcare DR…

2 months ago

Neutec Group Guides Buyers From Product Discovery to Product Validation With Bioz Badges

PALO ALTO, CA / ACCESS Newswire / October 21, 2025 / Bioz, Inc., a pioneering AI platform changing the way…

2 months ago

Only 27% of European Hospitals Achieve Full Patient Data Exchange Across Borders Despite EU Interoperability Mandates

Black Book survey reveals just 1 in 4 hospitals can fully exchange patient data across national boundaries in Q4 2025…

2 months ago

Collette Health Transforms Virtual Care Delivery with Vonage

Technology Partnership Improves Patient Outcomes in Healthcare Through Advanced Video API and Virtual Nursing Solutions HOLMDEL, N.J., Oct. 20, 2025…

2 months ago

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and…

2 months ago

Oscar Unveils New Choices and AI Tools Shaping the Future of Individual Healthcare for More Americans and Businesses

NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. (NYSE: OSCR), a leading healthcare technology company, is introducing a suite of easy-to-use health plans…

2 months ago

Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platform’s Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer

Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival…

2 months ago

Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in…

2 months ago

General Oncology Announces Promising Preliminary Phase 1 Results from SHARON Trial Presented at ESMO 2025

Novel regimen GO-4, combining melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cells shows manageable adverse reactions and a strong signal of efficacy in patients with BRCA-related…

2 months ago